Evaluation of Long-Term Inflammatory Responses after Implantation of a Novel Fully Bioabsorbable Scaffold Composed of Poly-L-lactic Acid and Amorphous Calcium Phosphate Nanoparticles
Table 3
Coronary artery serum levels of ALT, AST, UR, CR, and CRP.
Preimplant
1 month
6 months
12 months
24 months
ALT (U/L)
PLLA
49.17 ± 12.46
61.67 ± 19.98
65.33 ± 18.96
69.17 ± 17.57
64.00 ± 17.80
PLLA/ACP
51.17 ± 15.43
58.00 ± 26.80
71.67 ± 21.60
72.33 ± 24.04
58.83 ± 17.75
value
0.81
0.79
0.60
0.80
0.63
AST (U/L)
PLLA
38.33 ± 8.55
49.50 ± 18.92
56.83 ± 16.82
56.50 ± 21.84
54.33 ± 17.11
PLLA/ACP
38.00 ± 8.60
43.67 ± 18.85
60.33 ± 26.45
45.50 ± 28.23
51.33 ± 24.23
value
0.95
0.60
0.79
0.47
0.81
UR (mmol/l)
PLLA
5.13 ± 1.32
6.22 ± 1.05
5.77 ± 3.19
6.83 ± 3.02
6.80 ± 3.07
PLLA/ACP
4.50 ± 1.44
5.72 ± 1.72
6.38 ± 2.98
6.28 ± 2.99
7.25 ± 2.88
value
0.45
0.56
0.74
0.76
0.80
CR (μmol/l)
PLLA
78.83 ± 13.78
118.67 ± 25.56
92.17 ± 23.03
89.50 ± 28.89
113.17 ± 24.59
PLLA/ACP
84.00 ± 15.21
105.83 ± 23.92
104.33 ± 29.57
102.33 ± 29.84
100.50 ± 26.49
value
0.55
0.39
0.44
0.47
0.41
LDH (U/l)
PLLA
177.33 ± 66.01
300.67 ± 157.83
217.50 ± 81.45
193.33 ± 88.80
199.83 ± 120.87
PLLA/ACP
179.50 ± 46.47
243.67 ± 107.07
201.83 ± 35.89
232.33 ± 104.32
278.83 ± 111.24
value
0.95
0.48
0.68
0.50
0.27
CRP (mg/l)
PLLA
0.93 ± 0.47
1.64 ± 0.86
1.33 ± 0.53
1.71 ± 0.48
1.10 ± 0.51
PLLA/ACP
1.13 ± 0.44
1.75 ± 0.65
1.62 ± 0.41
1.28 ± 0.43
1.29 ± 0.64
values
0.47
0.79
0.33
0.14
0.58
Notes: Data are presented as mean ± standard deviation. values: the PLLA/ACP group compared with the PLLA group.
